Recent Updates
Recently added Catalysts

APG-3288

Phase 1

Relapsed/Refractory Hematological Malignancies | Small molecule | Oncology |Ascentage Pharma Group International - American Depository Shares|Last Updated: Feb 20, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment180
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07424833A Study of APG-3288 in Relapsed/Refractory Blood CancersPHASE1 NOT YET_RECRUITING 180 — — Mar 1, 2026Dec 1, 2031Feb 20, 20262 United States, China
Unlock Drug Trial Details
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
PurposeTREATMENT
Interventions
NameTypeDescription
APG-3288DRUGOrally administered daily; 28 days per cycle.
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT07424833studyFirstPostDate: changed